Skip to content
drillr.ai
Sign up

03759.HK

Pharmaron Beijing Co., Ltd.

HKSE · Healthcare · Biotechnology · CN

HKD 29.00
−2.03%
Ask drillr

  • Aug 26, 2026, 23:10 UTC

    Pharmaceutical R&D service company Pharmaron (03759) announced the proposed issuance of RMB 2.18 billion zero-coupon convertible bonds due 2027, priced at 102% of principal, with net proceeds of approximately USD 327.2 million to be used for business expansion, debt refinancing, and general corporate purposes.

    Source:

  • Aug 26, 2026, 11:45 UTC

    AI² Robotics and Pharmaron signed a strategic partnership agreement to combine AI² Robotics' embodied large model technology with Pharmaron's life sciences expertise, focusing on deploying embodied intelligence in pharmaceutical R&D and building smart lab ecosystems.

    Source:

  • Aug 25, 2026, 09:06 UTC

    JPMorgan increased its stake in Pharmaron Beijing's H shares from 7.48% to 8.60% on August 20, 2026, at an average price of HKD 34.0393 per share.

    Source:

  • Aug 24, 2026, 06:59 UTC

    Pharmaron Beijing's management raised its full-year revenue growth guidance from 12%-18% to 15%-20%, citing strong customer demand and orders in July and August.

    Source:

  • Aug 21, 2026, 02:27 UTC

    During the World Robot Conference, embodied intelligence company Zhipingfang signed two cooperation agreements: one with Pharmaron (strategic cooperation on embodied intelligence in life sciences and pharmaceutical R&D), and a tripartite framework agreement with Beijing Sanyuan Foods and Zhongyi (Shenzhen) Embodied Intelligence Technology to deploy embodied intelligence Aibao robots in Sanyuan's production and warehousing scenarios.

    Source:

  • Aug 20, 2026, 12:01 UTC

    Pharmaron Beijing Co., Ltd. announced its 2026 half-year results with net profit of 750 million yuan, up 6.96% year-on-year.

    Source:

  • Jul 14, 2026, 02:06 UTC

    Pharmaron Beijing Co., Ltd. issued a profit alert for the first half of 2026, expecting net profit to increase by 4-10% year-on-year.

    Source:

  • Jul 2, 2026, 08:12 UTC

    Pharmaron's shareholder Xinzhong Kangcheng and its concert party Xinzhong Longcheng reduced their holdings by 17.8 million shares from June 16 to July 1, 2026.

    Source:

  • Jun 29, 2026, 08:24 UTC

    Zhipingfang completed a funding round of approximately 5 billion yuan ($700 million), raising its valuation to over 20 billion yuan ($2.8 billion).

    Source: